US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
AU733551B2
(en)
|
1996-09-25 |
2001-05-17 |
Astrazeneca Ab |
Qinoline derivatives inhibiting the effect of growth factors such as VEGF
|
AU8816298A
(en)
|
1997-08-22 |
1999-03-16 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
AU5991699A
(en)
|
1998-09-21 |
2000-04-10 |
Biochem Pharma Inc. |
Quinolizinones as integrin inhibitors
|
JP3751201B2
(ja)
|
1999-02-27 |
2006-03-01 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
チロシンキナーゼにより媒介されるシグナル伝達に関する抑制効果を有する4−アミノ−キナゾリン誘導体及びキノリン誘導体
|
DE19911509A1
(de)
*
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
YU13200A
(sh)
*
|
1999-03-31 |
2002-10-18 |
Pfizer Products Inc. |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
KR100709909B1
(ko)
*
|
1999-06-21 |
2007-04-24 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
비사이클릭 헤테로사이클, 이를 함유하는 의약 조성물 및 이의 제조방법
|
WO2001004111A1
(en)
*
|
1999-07-09 |
2001-01-18 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
WO2001021596A1
(en)
|
1999-09-21 |
2001-03-29 |
Astrazeneca Ab |
Quinazoline derivatives and their use as pharmaceuticals
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
ATE398120T1
(de)
*
|
1999-11-05 |
2008-07-15 |
Astrazeneca Ab |
Neue quinazolin-derivate
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
AU2001231710A1
(en)
*
|
2000-02-09 |
2001-08-20 |
Novartis Ag |
Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
JP2003525897A
(ja)
|
2000-03-06 |
2003-09-02 |
アストラゼネカ アクチボラグ |
治 療
|
US20070021392A1
(en)
*
|
2000-03-31 |
2007-01-25 |
Davis Peter D |
Divided dose therapies with vascular damaging activity
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
EP1274692B1
(en)
*
|
2000-04-07 |
2006-08-02 |
AstraZeneca AB |
Quinazoline compounds
|
UA73993C2
(uk)
*
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
RU2267489C2
(ru)
|
2000-08-21 |
2006-01-10 |
Астразенека Аб |
Производные хиназолина, способ их получения и фармацевтическая композиция
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
DE10042061A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
AU2001292138A1
(en)
*
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
DE60144284D1
(de)
|
2000-11-01 |
2011-05-05 |
Millennium Pharm Inc |
Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
|
US7019012B2
(en)
*
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
DE60229046D1
(de)
|
2001-04-19 |
2008-11-06 |
Astrazeneca Ab |
Chinazolin derivate
|
WO2002092577A1
(en)
*
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
GB0126879D0
(en)
*
|
2001-11-08 |
2002-01-02 |
Astrazeneca Ab |
Combination therapy
|
GB0128108D0
(en)
*
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
GB0128109D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
CA2473572C
(en)
*
|
2002-02-01 |
2011-05-10 |
Astrazeneca Ab |
Quinazoline compounds
|
TW200813014A
(en)
*
|
2002-03-28 |
2008-03-16 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
JP2005536486A
(ja)
*
|
2002-07-09 |
2005-12-02 |
アストラゼネカ アクチボラグ |
癌の処置に使用するためのキナゾリン誘導体
|
ES2400339T3
(es)
*
|
2002-07-15 |
2013-04-09 |
Symphony Evolution, Inc. |
Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
AU2003255819A1
(en)
|
2002-08-24 |
2004-03-11 |
Astrazeneca Ab |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
GB0223380D0
(en)
*
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
US7462623B2
(en)
*
|
2002-11-04 |
2008-12-09 |
Astrazeneca Ab |
Quinazoline derivatives as Src tyrosine kinase inhibitors
|
ATE438644T1
(de)
|
2002-12-24 |
2009-08-15 |
Astrazeneca Ab |
Chinazolinderivate
|
ES2295816T3
(es)
|
2003-01-14 |
2008-04-16 |
Arena Pharmaceuticals, Inc. |
Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
|
US7223749B2
(en)
*
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
JO2785B1
(en)
*
|
2003-05-27 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
Quinazoline derivatives
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
CA2531862C
(en)
*
|
2003-07-10 |
2011-10-25 |
Astrazenca Ab |
Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
|
GB0316176D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
NZ617083A
(en)
|
2003-08-27 |
2015-04-24 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
DK1667991T3
(da)
|
2003-09-16 |
2008-08-18 |
Astrazeneca Ab |
Quinazolinderivater som tyrosinkinaseinhibitorer
|
EP1667996B1
(en)
*
|
2003-09-16 |
2009-07-22 |
Astrazeneca AB |
Quinazoline derivatives
|
US8318752B2
(en)
*
|
2003-09-19 |
2012-11-27 |
Astrazeneca Ab |
4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
|
ES2281007T3
(es)
*
|
2003-09-19 |
2007-09-16 |
Astrazeneca Ab |
Derivados de quinazolina.
|
MXPA06003341A
(es)
*
|
2003-09-25 |
2006-06-08 |
Astrazeneca Ab |
Derivados de quinazolina.
|
GB0322409D0
(en)
*
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP4638436B2
(ja)
|
2003-09-26 |
2011-02-23 |
エグゼリクシス, インコーポレイテッド |
c−Metモジュレーターおよびその使用
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2004293019B2
(en)
|
2003-11-19 |
2010-10-28 |
Array Biopharma Inc. |
Bicyclic inhibitors of MEK and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
ES2305887T3
(es)
*
|
2003-12-18 |
2008-11-01 |
Janssen Pharmaceutica Nv |
Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos.
|
EP1732920B1
(en)
|
2004-01-05 |
2011-03-09 |
AstraZeneca AB |
Thiophene derivatives as chk 1 inhibitors
|
ES2315834T3
(es)
|
2004-02-03 |
2009-04-01 |
Astrazeneca Ab |
Derivados de quinazolina.
|
CA2565812C
(en)
|
2004-05-06 |
2012-03-13 |
Warner-Lambert Company Llc |
4-phenylamino-quinazolin-6-yl-amides
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
CA2573103A1
(en)
*
|
2004-07-06 |
2006-02-09 |
Angion Biomedica Corporation |
Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
|
AU2005279045B2
(en)
|
2004-08-28 |
2009-11-26 |
Astrazeneca Ab |
Pyrimidine sulphonamide derivatives as chemokine receptor modulators
|
GB0424339D0
(en)
*
|
2004-11-03 |
2004-12-08 |
Astrazeneca Ab |
Combination therapy
|
JO3088B1
(ar)
*
|
2004-12-08 |
2017-03-15 |
Janssen Pharmaceutica Nv |
مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
PL1838733T3
(pl)
|
2004-12-21 |
2012-02-29 |
Medimmune Ltd |
Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
|
EP1844023A1
(en)
*
|
2004-12-31 |
2007-10-17 |
Sk Chemicals Co., Ltd. |
Quinazoline derivatives for the treatment and prevention of diabetes and obesity
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
CN101155800B
(zh)
|
2005-02-04 |
2012-05-23 |
阿斯利康(瑞典)有限公司 |
可用作激酶抑制剂的吡唑基氨基吡啶衍生物
|
WO2006090163A1
(en)
*
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
WO2006104059A1
(ja)
*
|
2005-03-28 |
2006-10-05 |
National Institute For Materials Science |
コバルトフリーのNi基超合金
|
WO2006119675A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d'une maladie tumorale
|
CN101175734B
(zh)
*
|
2005-05-12 |
2011-10-12 |
黄文林 |
一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
|
CN101175733A
(zh)
*
|
2005-05-12 |
2008-05-07 |
黄文林 |
一种酪氨酸激酶抑制剂、其制备方法及作为抗肿瘤药物的应用
|
CN101175732B
(zh)
*
|
2005-05-12 |
2010-06-16 |
黄文林 |
一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
|
ES2405785T3
(es)
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
EP2402316A1
(en)
|
2005-07-21 |
2012-01-04 |
AstraZeneca AB (Publ) |
Piperidine derivatives
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
JP2009508918A
(ja)
|
2005-09-20 |
2009-03-05 |
アストラゼネカ アクチボラグ |
癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物
|
WO2007034881A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
US20090105212A1
(en)
|
2005-09-22 |
2009-04-23 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
US20080269240A1
(en)
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US20090099216A1
(en)
|
2005-09-22 |
2009-04-16 |
Astrazeneca Aktiebolag A Corporation Of Sweden |
Novel adenine compound
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
US8148572B2
(en)
|
2005-10-06 |
2012-04-03 |
Astrazeneca Ab |
Compounds
|
AU2006201635A1
(en)
*
|
2005-10-20 |
2007-05-10 |
Ludwig Institute For Cancer Research |
Novel inhibitors and methods for their preparation
|
AU2006307657B2
(en)
|
2005-10-28 |
2010-10-28 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
US8404697B2
(en)
|
2005-11-11 |
2013-03-26 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
PT2090575E
(pt)
|
2005-11-15 |
2011-06-06 |
Array Biopharma Inc |
Inibidores de erbb
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
RS52357B
(en)
|
2005-12-13 |
2012-12-31 |
Medimmune Limited |
BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
|
ATE545637T1
(de)
|
2005-12-15 |
2012-03-15 |
Astrazeneca Ab |
Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
|
US20070213319A1
(en)
*
|
2006-01-11 |
2007-09-13 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CN102558021A
(zh)
|
2006-05-26 |
2012-07-11 |
阿斯利康(瑞典)有限公司 |
联芳基或芳基-杂芳基取代的吲哚类化合物
|
AU2007274284B2
(en)
|
2006-07-13 |
2012-04-26 |
Janssen Pharmaceutica N.V. |
Mtki quinazoline derivatives
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
MY148688A
(en)
|
2006-08-23 |
2013-05-31 |
Kudos Pharm Ltd |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
EP2061772A4
(en)
*
|
2006-09-11 |
2011-06-29 |
Curis Inc |
MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
|
AU2007296745B2
(en)
*
|
2006-09-11 |
2011-12-01 |
Curis, Inc. |
Quinazoline based EGFR inhibitors
|
SG174774A1
(en)
*
|
2006-09-11 |
2011-10-28 |
Curis Inc |
Quinazoline based egfr inhibitors containing a zinc binding moiety
|
NZ576065A
(en)
*
|
2006-09-18 |
2011-12-22 |
Boehringer Ingelheim Int |
Method for treating cancer harboring egfr mutations
|
EP2066353B1
(en)
|
2006-09-29 |
2013-01-02 |
AstraZeneca AB |
Combination of zd6474 and bevacizumab for cancer therapy
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
US7799954B2
(en)
|
2006-11-17 |
2010-09-21 |
Abraxis Bioscience, Llc |
Dicarbonyl derivatives and methods of use
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
KR20090094460A
(ko)
|
2006-12-19 |
2009-09-07 |
아스트라제네카 아베 |
무스카린 수용체 길항제로서 퀴누클리디놀 유도체
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
MX2009007610A
(es)
|
2007-02-06 |
2009-07-24 |
Boehringer Ingelheim Int |
Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
JP5536647B2
(ja)
|
2007-07-27 |
2014-07-02 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ピロロピリミジン
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
US8119616B2
(en)
*
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
NZ584160A
(en)
|
2007-10-04 |
2011-05-27 |
Astrazeneca Ab |
Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
|
WO2009047563A1
(en)
|
2007-10-11 |
2009-04-16 |
Astrazeneca Ab |
Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
|
JP2011502141A
(ja)
|
2007-10-29 |
2011-01-20 |
ナトコ ファーマ リミテッド |
抗癌剤としての4‐(テトラゾール‐5‐イル)‐キナゾリン誘導体
|
PL2690101T3
(pl)
|
2007-12-19 |
2015-12-31 |
Genentech Inc |
5-anilinoimidazopirydyny i sposoby zastosowania
|
ES2387707T3
(es)
|
2007-12-21 |
2012-09-28 |
Genentech, Inc. |
Azaindolizinas y procedimientos de uso
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
CA2708871C
(en)
|
2007-12-21 |
2017-11-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
|
CA2712367C
(en)
|
2008-01-17 |
2016-01-19 |
Bayer Schering Pharma Aktiengesellschaft |
Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
|
SI2245026T1
(sl)
|
2008-02-07 |
2012-12-31 |
Boehringer Ingelheim International Gmbh |
Spirociklični heterocikli, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo
|
BRPI0908100A2
(pt)
*
|
2008-02-21 |
2015-10-06 |
Astrazeneca Ab |
produto combinação, uso de um composto, e, método de tratar câncer
|
CN101952287B
(zh)
|
2008-02-28 |
2013-11-27 |
默克专利有限公司 |
蛋白激酶抑制剂及其应用
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
AU2009252938B2
(en)
|
2008-05-27 |
2012-04-26 |
Astrazeneca Ab |
Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
CN102137843A
(zh)
|
2008-07-01 |
2011-07-27 |
健泰科生物技术公司 |
作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
WO2010015522A1
(de)
|
2008-08-08 |
2010-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CN101659657B
(zh)
*
|
2008-08-29 |
2014-05-14 |
北大方正集团有限公司 |
氰基取代的喹啉衍生物及其制备方法和用途
|
CN101659658B
(zh)
*
|
2008-08-29 |
2014-04-02 |
北大方正集团有限公司 |
氰基取代的喹啉衍生物
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
US9012495B2
(en)
|
2008-12-11 |
2015-04-21 |
Axcentua Pharmaceuticals Ab |
Crystalline forms of genistein
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
EP2367821B1
(en)
|
2008-12-17 |
2015-09-16 |
Merck Patent GmbH |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
AU2009336040B2
(en)
|
2008-12-18 |
2015-07-16 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
TWI577664B
(zh)
|
2009-01-16 |
2017-04-11 |
艾克塞里克斯公司 |
N-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途
|
KR101984053B1
(ko)
|
2009-02-05 |
2019-05-30 |
이뮤노젠 아이엔씨 |
신규한 벤조디아제핀 유도체
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
EA019647B1
(ru)
|
2009-02-10 |
2014-05-30 |
Астразенека Аб |
ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
SI2451445T1
(sl)
|
2009-07-06 |
2019-07-31 |
Boehringer Ingelheim International Gmbh |
Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
US8916574B2
(en)
|
2009-09-28 |
2014-12-23 |
Qilu Pharmaceutical Co., Ltd. |
4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
KR20120099639A
(ko)
|
2009-10-02 |
2012-09-11 |
아스트라제네카 아베 |
호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
JP5657018B2
(ja)
|
2009-11-18 |
2015-01-21 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
ベンゾイミダゾール化合物及びその使用
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
WO2011072791A1
(de)
|
2009-12-14 |
2011-06-23 |
Merck Patent Gmbh |
Inhibitoren der sphingosinkinase
|
KR20120096076A
(ko)
|
2009-12-17 |
2012-08-29 |
메르크 파텐트 게엠베하 |
스핑고신 키나아제 저해제
|
CN102203112B
(zh)
|
2010-01-15 |
2014-05-07 |
苏州润新生物科技有限公司 |
某些化合物、组合物及方法
|
MX2012008328A
(es)
|
2010-01-19 |
2012-08-08 |
Astrazeneca Ab |
Derivados de pirazina.
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
TWI406853B
(zh)
*
|
2010-04-07 |
2013-09-01 |
Dev Center Biotechnology |
Egfr與vegfr-2雙重抑制劑及其用途與製法
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
KR101217526B1
(ko)
*
|
2010-06-11 |
2013-01-02 |
한미사이언스 주식회사 |
아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
|
WO2012000182A1
(en)
*
|
2010-06-30 |
2012-01-05 |
Hutchison Medipharma Limited |
Quinazoline compounds
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
US9018197B2
(en)
|
2010-08-28 |
2015-04-28 |
Suzhou Neupharma Co. Ltd. |
Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
|
WO2012040279A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
WO2012067268A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
WO2012080730A1
(en)
|
2010-12-17 |
2012-06-21 |
Astrazeneca Ab |
Purine derivatives
|
RU2013133846A
(ru)
|
2010-12-20 |
2015-01-27 |
Медиммьюн Лимитед |
Антитела против il-18 и их применение
|
WO2012103810A1
(en)
|
2011-02-02 |
2012-08-09 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
WO2012112708A1
(en)
|
2011-02-15 |
2012-08-23 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and methods of preparation
|
DK2675794T3
(da)
|
2011-02-17 |
2019-05-06 |
Cancer Therapeutics Crc Pty Ltd |
Selektive fak-inhibitorer
|
CN103534241B
(zh)
|
2011-02-17 |
2015-11-25 |
癌症疗法Crc私人有限公司 |
Fak抑制剂
|
SG193291A1
(en)
|
2011-03-04 |
2013-10-30 |
Newgen Therapeutics Inc |
Alkyne substituted quinazoline compound and methods of use
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
KR101317809B1
(ko)
|
2011-06-07 |
2013-10-16 |
한미약품 주식회사 |
암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EA027821B1
(ru)
|
2011-07-12 |
2017-09-29 |
Астразенека Аб |
N-(6-((2r,3s)-3,4-дигидроксибутан-2-илокси)-2-(4-фторбензилтио)пиримидин-4-ил)-3-метилазетидин-1-сульфонамид в качестве модулятора рецептора хемокина
|
EA029488B1
(ru)
|
2011-07-27 |
2018-04-30 |
Астразенека Аб |
Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
ES2725790T3
(es)
|
2011-08-26 |
2019-09-27 |
Neupharma Inc |
Algunas entidades químicas, composiciones, y métodos
|
US9328081B2
(en)
|
2011-09-01 |
2016-05-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP6093768B2
(ja)
|
2011-09-14 |
2017-03-08 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
WO2013045955A1
(en)
|
2011-09-29 |
2013-04-04 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
WO2013049701A1
(en)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
ES2655264T3
(es)
|
2012-01-28 |
2018-02-19 |
Merck Patent Gmbh |
Derivados de triazolo[4,5-d]pirimidina
|
KR20140120371A
(ko)
|
2012-02-09 |
2014-10-13 |
메르크 파텐트 게엠베하 |
Tbk1 및 ikk 저해제로서의 푸로 [3, 2 - b] - 및 티에노 [3, 2 - b] 피리딘 유도체
|
PE20141823A1
(es)
|
2012-02-09 |
2014-11-29 |
Merck Patent Gmbh |
Derivados de tetrahidro-quinazolinona
|
JP6097770B2
(ja)
|
2012-02-21 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
フロピリジン誘導体
|
WO2013126132A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
WO2013124026A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
|
ES2579981T3
(es)
|
2012-03-07 |
2016-08-18 |
Merck Patent Gmbh |
Derivados de triazolopirazina
|
EP2752413B1
(en)
|
2012-03-26 |
2016-03-23 |
Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences |
Quinazoline derivative and application thereof
|
WO2013143663A1
(en)
|
2012-03-28 |
2013-10-03 |
Merck Patent Gmbh |
Bicyclic pyrazinone derivatives
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
WO2013150043A1
(en)
|
2012-04-05 |
2013-10-10 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
US9676813B2
(en)
|
2012-04-29 |
2017-06-13 |
Neupharma, Inc. |
Certain steroids and methods for using the same in the treatment of cancer
|
SI2844659T1
(sl)
|
2012-05-04 |
2016-10-28 |
Merck Patent Gmbh |
Pirolotriazinonski derivati
|
SG11201408161RA
(en)
|
2012-06-08 |
2015-01-29 |
Sutro Biopharma Inc |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
US9624264B2
(en)
|
2012-07-24 |
2017-04-18 |
Merck Patent Gmbh |
Hydroxystatin derivatives for the treatment of arthrosis
|
EP2882746B1
(en)
|
2012-08-07 |
2016-12-07 |
Merck Patent GmbH |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
WO2014023390A2
(en)
|
2012-08-08 |
2014-02-13 |
Merck Patent Gmbh |
(aza-)isoquinolinone derivatives
|
US20160009686A1
(en)
|
2012-08-17 |
2016-01-14 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
SI3584255T1
(sl)
|
2012-08-31 |
2022-05-31 |
Sutro Biopharma, Inc |
Modificirane aminokisline, ki vsebujejo azido skupino
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
US9688635B2
(en)
|
2012-09-24 |
2017-06-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RU2650107C2
(ru)
|
2012-09-26 |
2018-04-09 |
Мерк Патент Гмбх |
Производные хиназолинона в качестве ингибиторов parp
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
WO2014066955A1
(en)
|
2012-11-05 |
2014-05-08 |
Lindley Robyn Alice |
Methods for determining the cause of somatic mutagenesis
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
WO2014075754A1
(en)
|
2012-11-16 |
2014-05-22 |
Merck Patent Gmbh |
3-aminocyclopentane carboxamide derivatives
|
KR20140096571A
(ko)
|
2013-01-28 |
2014-08-06 |
한미약품 주식회사 |
1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
|
AU2014211962B2
(en)
|
2013-01-31 |
2017-11-16 |
Bellus Health Cough Inc. |
Imidazopyridine compounds and uses thereof
|
AU2014221010B2
(en)
|
2013-02-25 |
2018-06-14 |
Merck Patent Gmbh |
2-amino -3,4-dihydro-quinazoline derivatives and the use thereof as cathepsin D inhibitors
|
US9999680B2
(en)
|
2013-02-28 |
2018-06-19 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
|
EP2961435B1
(en)
|
2013-02-28 |
2019-05-01 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
JP6409007B2
(ja)
|
2013-03-05 |
2018-10-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗癌剤としての9−(アリールまたはヘテロアリール)−2−(ピラゾリル、ピロリジニルまたはシクロペンチル)アミノプリン誘導体
|
CN105142648A
(zh)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
用于癌症的镁组合物及其用途
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
EP3013424A4
(en)
|
2013-06-25 |
2017-03-29 |
University of Canberra |
Methods and compositions for modulating cancer stem cells
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
CA2921410C
(en)
|
2013-08-23 |
2023-03-28 |
Neupharma, Inc. |
Quinazoline derivatives, compositions and their use as kinase inhibitors
|
WO2015031604A1
(en)
|
2013-08-28 |
2015-03-05 |
Crown Bioscience, Inc. |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|
SG11201601408PA
(en)
|
2013-09-18 |
2016-04-28 |
Univ Canberra |
Stem cell modulation ii
|
EP3052660A4
(en)
|
2013-10-01 |
2017-04-26 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
US10011587B2
(en)
|
2014-05-15 |
2018-07-03 |
The Methodist Hospital System |
Multivalent ligands targeting VEGFR
|
CN105330653A
(zh)
*
|
2014-08-11 |
2016-02-17 |
石药集团中奇制药技术(石家庄)有限公司 |
喹唑啉衍生物
|
CA2958704A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
ES2883628T3
(es)
|
2014-11-17 |
2021-12-09 |
Univ Queensland |
Biomarcadores de glucoproteínas para adenocarcinoma de esófago y esófago de Barrett y usos de los mismos
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
US10947201B2
(en)
|
2015-02-17 |
2021-03-16 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
MA42807A
(fr)
|
2015-06-22 |
2018-07-25 |
Arena Pharm Inc |
Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
|
CA2994023A1
(en)
|
2015-08-04 |
2017-02-02 |
University Of South Australia |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
ES2873841T3
(es)
|
2015-08-26 |
2021-11-04 |
Gmdx Co Pty Ltd |
Métodos para detectar la recurrencia del cáncer
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
GB201519568D0
(en)
|
2015-11-05 |
2015-12-23 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
US11534451B2
(en)
|
2015-12-23 |
2022-12-27 |
Repluca Pty Ltd |
Nucleic acid oligomers and uses therefor
|
KR20180104106A
(ko)
|
2016-01-27 |
2018-09-19 |
서트로 바이오파마, 인크. |
anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
|
JP7341451B2
(ja)
|
2016-02-01 |
2023-09-11 |
エピアクシス セラピューティクス プロプライアタリー リミティド |
タンパク質性化合物とその利用
|
GB201604182D0
(en)
|
2016-03-11 |
2016-04-27 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
BR112018068347A2
(pt)
|
2016-03-21 |
2019-01-15 |
Astrazeneca Ab |
compostos de cinolin-4-amina e seu uso no tratamento de câncer
|
KR20180132804A
(ko)
|
2016-04-07 |
2018-12-12 |
아스트라제네카 아베 |
암 치료를 위한 atm(모세관확장실조 돌연변이) 키나제 조정자로서의 n,n-디메틸-3-[[5-(3-메틸-2-옥소-1-테트라하이드로피란-4-일-이미다조[4,5-c]퀴놀린-8-일)-2-피리딜]옥시]프로판-1-아민 옥시드
|
CN105853434A
(zh)
*
|
2016-04-13 |
2016-08-17 |
李春 |
一种治疗正畸儿童牙龈炎的药物组合物
|
EP4104837A3
(en)
|
2016-04-15 |
2023-04-26 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
GB201608227D0
(en)
|
2016-05-11 |
2016-06-22 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2018035061A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
US10919896B2
(en)
|
2016-09-22 |
2021-02-16 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
BR112019011284A2
(pt)
|
2016-12-05 |
2019-10-22 |
Apros Therapeutics Inc |
composto, composição farmacêutica, métodos de tratamento de uma condição, de hbv e de câncer, e, uso de um composto.
|
MY183036A
(en)
|
2016-12-20 |
2021-02-08 |
Astrazeneca Ab |
Amino-triazolopyridine compounds and their use in treating cancer
|
US11111245B2
(en)
|
2017-02-01 |
2021-09-07 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
JOP20190209A1
(ar)
|
2017-03-16 |
2019-09-12 |
Astrazeneca Ab |
مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
JP7202315B2
(ja)
|
2017-05-26 |
2023-01-11 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ベンズイミダゾロン由来のbcl6阻害剤
|
EP3630749B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
DK3630188T3
(da)
|
2017-05-31 |
2021-11-15 |
Amplio Pharma Ab |
Farmaceutisk sammensætning omfattende en kombination af methotrexat og novobiocin og anvendelse af sammensætningen til behandling
|
US11400160B2
(en)
|
2017-07-05 |
2022-08-02 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
RS64035B1
(sr)
|
2017-08-01 |
2023-04-28 |
Merck Patent Gmbh |
Derivati tiazolopiridina kao antagonisti receptora adenozina
|
EP3668882A1
(en)
|
2017-08-18 |
2020-06-24 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
AU2018320672B2
(en)
|
2017-08-21 |
2023-09-07 |
Merck Patent Gmbh |
Quinoxaline derivatives as adenosine receptor antagonists
|
JP7287952B2
(ja)
|
2017-08-21 |
2023-06-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
|
RU2020111503A
(ru)
|
2017-09-18 |
2021-10-20 |
Сутро Биофарма, Инк. |
Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение
|
WO2019057757A1
(en)
|
2017-09-20 |
2019-03-28 |
Astrazeneca Ab |
1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
KR20200104291A
(ko)
|
2017-11-06 |
2020-09-03 |
랩트 테라퓨틱스, 인크. |
항암제
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
EP3488868B1
(en)
|
2017-11-23 |
2023-09-13 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
|
WO2019136514A1
(en)
|
2018-01-15 |
2019-07-18 |
University Of South Australia |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
US10683280B2
(en)
|
2018-01-26 |
2020-06-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
JP2021512893A
(ja)
|
2018-02-08 |
2021-05-20 |
ニューファーマ,インク. |
特定の化学物質、組成物、および方法
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
MX2020010805A
(es)
|
2018-04-13 |
2021-01-29 |
Cancer Research Tech Ltd |
Inhibidores de bcl6.
|
EP3784233B1
(en)
|
2018-04-27 |
2024-06-05 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
US10857153B2
(en)
|
2018-06-04 |
2020-12-08 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
CA3099776A1
(en)
|
2018-09-18 |
2020-03-26 |
Suzhou Zanrong Pharma Limited |
Quinazoline derivatives as antitumor agents
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
AU2019363662A1
(en)
|
2018-10-25 |
2021-03-25 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
MX2021003508A
(es)
|
2018-10-25 |
2021-05-27 |
Merck Patent Gmbh |
Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
CN114729354A
(zh)
|
2018-12-25 |
2022-07-08 |
中国医学科学院基础医学研究所 |
炎性相关疾病防治的小rna药物及其组合
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
JP2022524759A
(ja)
|
2019-03-07 |
2022-05-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
US20230085408A1
(en)
|
2019-04-05 |
2023-03-16 |
STORM Therapeutics Ltd. |
Mettl3 inhibitory compounds
|
CA3127475A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
AU2020279686A1
(en)
|
2019-05-21 |
2021-12-16 |
Voronoi Inc. |
N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
JP2022545930A
(ja)
|
2019-08-31 |
2022-11-01 |
上海奕拓醫藥科技有限責任公司 |
Fgfr阻害剤とするピラゾール類誘導体及びその調製方法
|
CN114555593A
(zh)
|
2019-09-20 |
2022-05-27 |
伊迪亚生物科学有限公司 |
作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
AU2020394867A1
(en)
|
2019-12-02 |
2022-05-26 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as METTL3 inhibitors
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
CA3196595A1
(en)
*
|
2020-09-25 |
2022-03-31 |
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd |
Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
EP3992191A1
(en)
|
2020-11-03 |
2022-05-04 |
Deutsches Krebsforschungszentrum |
Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
|
CN114948964B
(zh)
*
|
2021-02-25 |
2023-10-03 |
石药集团中奇制药技术(石家庄)有限公司 |
多靶点蛋白激酶抑制剂的用途
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
CN117396231A
(zh)
|
2021-04-30 |
2024-01-12 |
新基公司 |
使用抗BCMA抗体药物缀合物(ADC)与γ分泌酶抑制剂(GSI)的组合的组合疗法
|
CN117222435A
(zh)
|
2021-05-03 |
2023-12-12 |
默克专利有限公司 |
HER2靶向Fc抗原结合片段-药物缀合物
|
KR20220156448A
(ko)
|
2021-05-17 |
2022-11-25 |
에이치케이이노엔 주식회사 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
CA3221411A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
WO2023057389A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023186881A1
(en)
|
2022-03-29 |
2023-10-05 |
Baden-Württemberg Stiftung Ggmbh |
P38 map kinase inhibitors for use in the treatment of colorectal cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024006542A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|